J&J To Buy Psychiatric Drug Developer Intra-Cellular For $14.6 Billion

Johnson & Johnson and Intra-Cellular Therapies, Inc. entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, which develops psychiatric drugs. The deal is valued at $14.6 billion. Intra-Cellular is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. ;Intra-Cellular Therapies’ flagship medication is CAPLYTA, a once-daily oral therapy approved by the FDA to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive . . .